DELBio, a member of the Delta Group, Taiwan, is a developer and manufacturer of medical products focusing on diabetes care, respiratory care, medical imaging system and IVD.
The growth of global population and advancing of modern transportation have not only greatly promoted international trade and economic development, but also resulted in aggravated spreading of infectious diseases. Therefore, clinical medicine were seeking the solutions of on-site (or termed point-of-care-testing, POCT) diagnostics for suspected cases, in order to detect and prevent diseases at early stages. However, the majority of common POCT diagnostics based on immune-based methods, though capable of obtaining preliminary analysis at a short turn-around-time, still suffered by their poor sensitivity. On the contrary, molecular diagnostics is capable of detecting target pathogens with superior sensitivity and accuracy. However, conventional molecular diagnostics are processed by well-trained technicians at central laboratories and therefore is unable to satisfy the immediately disease control purpose due to long turn-around-time. This is because the operation of molecular diagnostics relies on specific controlled environments, a group of expensive laboratory instruments and sophisticated working protocols. In order to solve abovementioned issues, DELBio Inc. developed a “sample to answer” nucleic acid based diagnostic platform named G1: Automated Nucleic Acid Analysis platform, by integrating various technologies and know-hows such as nucleic acid reaction technologies, microfluidic biochip, optics, electronics, mechanics, thermal control and etc. into a desktop platform. G1: Automated Nucleic Acid Analysis platform can simultaneously detect for a suspected sample within 50- 90 minutes and is aiming at offering infectious disease control required solutions with ease of operation, high accuracy and point-of-care diagnostics. It is highly expected that this platform can supply the gap between molecular diagnostic technology and POCT, and facilitate the effective infectious diseases control in the near future.
Are you a reagent supplier or interested in product OEM? Meeting DELBio at the upcoming Expo or via Healthcare+ B2B.
